BOHUI BIO
BOHUI BIO
Industry:
Biotechnology
Founded:
2018-03-01
Address:
Daxing, Beijing, China
Country:
China
Website Url:
http://www.broadenbio.com
Total Employee:
11+
Status:
Active
Contact:
010-58222729
Email Addresses:
[email protected]
Total Funding:
10 M CNY
Investors List
Tao Capital
Tao Capital investment in Seed Round - Bohui Bio
More informations about "Bohui Bio"
BroadenBio
伯汇生物拥有独特的免疫技术平台，集肿瘤与自身免疫病新靶点的发现与鉴定、体内体外免疫功能检测与药物评价功能于一体；化学服务平台涵盖工艺开发与优化、定制合成及注册申报等业务。See details»
BroadenBio 2025 Company Profile: Valuation, Funding & Investors …
BroadenBio General Information Description. Developer of a biological technology designed to overcome tumors and immune diseases. The company focuses on research and development …See details»
BroadenBio - Products, Competitors, Financials, Employees, …
BroadenBio was founded in 2018. Where is BroadenBio's headquarters? BroadenBio's headquarters is located at 6th Floor, Building A1, Yard 88, Kechuang 6th Street, Beijing …See details»
BroadenBio - VentureRadar
Since its foundation, BroadenBio has received the investment of many well-known institutions, and has established a unique immunology platform and a molecular conjugation technology …See details»
Beijing BroadenBio Co., Ltd. - Drug pipelines, Patents, Clinical trials ...
Explore Beijing BroadenBio Co., Ltd. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, and 3 literature, Disease Domain:Neoplasms, Hemic and Lymphatic Diseases, …See details»
BroadenBio Co., Ltd. - CMOCRO
BroadenBio Co., Ltd. is a burgeoning biotechnology company in the clinical stage, specializing in oncology and autoimmune diseases. With significant investments from renowned institutions, …See details»
BroadenBio Co., Ltd. _Company Profile
BroadenBio Co., Ltd. ("BroadenBio"), co-founded by senior experts on drug discovery and development returning to China from overseas big pharmaceutical companies, is a growing …See details»
Beijing BroadenBio Co., Ltd. - synapse.zhihuiya.com
了解Beijing BroadenBio Co., Ltd. (北京伯汇生物技术有限公司)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 6篇新闻和3篇文献，疾病领域:肿瘤，血液及淋巴系统疾病，感 …See details»
BroadenBio Co., Ltd. -Core Team
Address： A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176. phone： 010-58222729. e-mail： [email protected]See details»
BrodenBio Completed the Pre-A Round of Financing of Tens of …
BroadenBio Co., Ltd. _Innovative drug research and development company in the clinical stage, jointly establishedSee details»
BroadenBio Co., Ltd. -Fields
The research and development fields of BroadenBio focus on oncology, viral infections and autoimmune diseases. All these fields have huge medical needs and markets, as well as …See details»
team-BroadenBio Co., Ltd.
BroadenBio Co., Ltd. team Innovative drug research and development company in the clinical stage, jointly establishedSee details»
公司简介_北京伯汇生物技术有限公司 新药 ... - BroadenBio
北京伯汇生物技术有限公司 新药研发|研发管线_伯汇生物是一家处于临床阶段的创新药物研发公司，由来自海外知名药企的资深药物研发专家归国共同创建，聚焦肿瘤以及自身免疫性疾病See details»
BIO Announces Dedicated Focus on Human Health and …
1 day ago Washington, DC, May 28, 2025 – The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work …See details»
张兴民_北京伯汇生物技术有限公司 新药研发|研发管线
北京伯汇生物技术有限公司 新药研发|研发管线_伯汇生物是一家处于临床阶段的创新药物研发公司，由来自海外知名药企的资深药物研发专家归国共同创建，聚焦肿瘤以及自身免疫性疾病See details»
伯汇生物BB3008获得FDA批准开展晚期实体瘤 ... - BroadenBio
近日，北京伯汇生物技术有限公司（伯汇生物）自主研发的造血祖细胞激酶1（hpk1）选择性小分子抑制剂bb3008的临床试验申请（ind）获得美国fda批准，同意开展bb3008针对晚期实体瘤 …See details»
Shifeng Wei Ph.D._BroadenBio Co., Ltd.
Dr. Shifeng Wei, Co-founder and general manager of Innovaco Pharmeceuticals, Inc. Graduated from Peking University School of Pharmaceutical Sciences (formerly Pharmaceutical Sciences …See details»
伯汇生物BB102临床Ⅰ期研究在中国完成首例 ... - BroadenBio
2023年1月5日，北京伯汇生物技术有限公司（简称“伯汇生物”）独立自主研发的高选择性小分子抑制剂 bb102在河南省肿瘤医院顺利完成Ⅰ期临床首例受试者入组和给药 ，标志着此项目临床 …See details»
公司新闻-北京伯汇生物技术有限公司 新药 ... - BroadenBio
伯汇生物BB102再次获得FDA孤儿药资格认定 2024年11月4日，北京伯汇生物技术有限公司（伯汇生物）自主研发的新一代FGFR4抑制剂BB102获得美国食品药品监督管理局（FDA）授予的 …See details»
伯汇生物新一代FGFR4抑制剂BB102获FDA授予治疗软组织肉瘤的孤 …
BroadenBio 2 0 24年7月2日，北京伯汇生物技术有限公司（伯汇生物）在研的FGFR4抑制剂BB102获得美国食品药品监督管理局（FDA）授予的孤儿药资格认定，用于治疗软组织肉 …See details»